Successful abatacept treatment for Felty's syndrome in a patient with rheumatoid arthritis

Mod Rheumatol Case Rep. 2020 Jul;4(2):168-170. doi: 10.1080/24725625.2020.1717740. Epub 2020 Jan 30.

Abstract

We report the case of a 69-year-old man with a 38-year history of rheumatoid arthritis (RA), who developed Felty's syndrome, successful treatment with abatacept (ABT). He was treated with etanercept 50 mg/w and methotrexate 8 mg/w for the past 5 years. He was suffered from febrile neutropenia 6 months ago. Etanercept and methotrexate was discontinued 3 months ago, however, neutrophil count was not changed. Abdominal ultrasound showed splenomegaly, the diagnosis of Felty's syndrome was made. Granulocyte colony-stimulating factor therapy showed no effect on neutropenia, he was treated with ABT. After ABT therapy, absolute neutrophil count was elevated 234/μL to 1840/μL.

Keywords: Felty’s syndrome; Rheumatoid arthritis; abatacept; extra-manifestation; neutropenia.

Publication types

  • Case Reports

MeSH terms

  • Abatacept / administration & dosage
  • Abatacept / therapeutic use*
  • Aged
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / complications*
  • Arthritis, Rheumatoid / drug therapy
  • Disease Management
  • Felty Syndrome / diagnosis
  • Felty Syndrome / drug therapy*
  • Felty Syndrome / etiology*
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Leukocyte Count
  • Male
  • Neutrophils
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Immunosuppressive Agents
  • Abatacept